S3 Connected Health provides Affinial, a Cloud-based Therapy Management Platform.
The platform is provided to pharmaceutical companies and uses real-time, predictive analytics and evidence based behavior change models to improve patient engagement, adherence and persistence.
Through dynamic profiling, predictive analytics, connected technologies and personalized interventions, Affinial engages patients, making them feel informed, understood, in control, and safe. This enables individualized engagements that supports patients in managing their therapy and condition, and make a real difference to patient outcomes.
Affinial provides real-time, real world data – to give oversight to clinicians and carers, and also valuable evidence and insight into patient’s condition management to pharma brand managers.
- Measure and increase adherence to medication
- Generate evidence that will support payor, provider, prescribing and clinical decision making
- Deliver patient-generated insight that will support pharma brand managers into reasons for non-adherence, inform planning and decision-making
Problems addressed by Initiative
Non-adherence to prescribed medication or therapy is a significant challenge.
Affinial addresses the following issues which pharmaceutical companies face, be it at Trial, Launch or In-Market:
- Is medication or therapy taken as directed?
- Do you have real-world evidence that supports prescribing and funding decisions?
- Is your medication or therapy supported by real-time insights that inform planning and decision-making?
We believe Connected Health will transform healthcare delivery and improve quality of life for millions of people. Connected health will change how patients and clinicians interact. It will change how patients feel ab...